These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1027718)

  • 21. Effects of non-steroidal anti-inflammatory drugs on human leucocytes.
    Wildfeuer A
    Z Rheumatol; 1983; 42(1):16-20. PubMed ID: 6845886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of antitumor chemoimmunotherapy with bone marrow macrophage precursor cell stimulation and macrophage cytotoxicity.
    Fisher B; Wolmark N
    Cancer Res; 1976 Jul; 36(7 PT 1):2241-7. PubMed ID: 1277129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
    Berd D; Mastrangelo MJ
    Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of cytotoxic polymorphonuclear leukocytes by in vivo administration of a streptococcal preparation, OK-432.
    Watabe S; Sendo F; Kimura S; Arai S
    J Natl Cancer Inst; 1984 Jun; 72(6):1365-70. PubMed ID: 6587156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclophosphamide suppression of established cell-mediated immunity. Quantitative vs. qualitative changes in lymphocyte populations.
    Balow JE; Hurley DL; Fauci AS
    J Clin Invest; 1975 Jul; 56(1):65-70. PubMed ID: 1095612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmentation of human natural killer cell activity by cyclophosphamide in vitro.
    Sharma B; Vaziri ND
    Cancer Res; 1984 Aug; 44(8):3258-61. PubMed ID: 6589041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.
    Berd D; Maguire HC; Mastrangelo MJ
    Cancer Res; 1984 Mar; 44(3):1275-80. PubMed ID: 6229330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of cyclophosphamide on antibody formation in the mouse.
    Willers JM; Sluis E
    Ann Immunol (Paris); 1975 Apr; 126(3):267-79. PubMed ID: 1101799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of combined administration of cytembena and cyclophosphamide on the blood count and morphology of nucleoli in peripheral-blood lymphocytes in patients with malignant tumors.
    Matĕjková E
    Neoplasma; 1975; 22(1):45-54. PubMed ID: 1173938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of corticosteroid action on lymphocyte subpopulations. II. Differential effects of in vivo hydrocortisone, prednisone and dexamethasone on in vitro expression of lymphocyte function.
    Fauci AS
    Clin Exp Immunol; 1976 Apr; 24(1):54-62. PubMed ID: 1084818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elimination of immune suppressor mechanisms in humans by oxazaphosphorines.
    Berd D; Mastrangelo MJ
    Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):569-77. PubMed ID: 2963936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
    Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
    Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow and peripheral blood modifications in C57BL mice administered with cyclophosphamide and levan.
    Siegal A; Kopel S; Bar-Sela S; Davidai G; Yavetz H; Leibovici J
    In Vivo; 1988; 2(5):349-59. PubMed ID: 2979857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of polymorphonuclear leukocyte-mediated cytotoxicity by hydrocortisone "in vitro".
    Capsoni F; Meroni PL; Zocchi MR; Plebani A
    Boll Ist Sieroter Milan; 1981 May; 60(2):113-20. PubMed ID: 7306390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
    Bonavida B; Lebow LT; Bradley TP
    J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions.
    Boerrigter GH; Scheper RJ
    Clin Exp Immunol; 1984 Oct; 58(1):161-6. PubMed ID: 6478648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of the relation between suppressor and effector mechanisms in contact sensitivity in the guinea-pig.
    Parker D; Turk JL
    Immunology; 1982 Sep; 47(1):61-6. PubMed ID: 6214499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a leukocytopenic baby guinea pig model with azathioprine and cyclophosphamide.
    Kumar A; Leonard MC; Cleveland RP
    Comp Immunol Microbiol Infect Dis; 1989; 12(4):91-4. PubMed ID: 2612136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-dependent cellular cytotoxicity by polymorphonuclear leucocytes in patients with AIDS and AIDS-related complex.
    Kinne TJ; Gupta S
    J Clin Lab Immunol; 1989 Dec; 30(4):153-6. PubMed ID: 2642173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.